Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
PaperCitations, authors & open-access status
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 917 citations, 2020 year and closed oa status.
917
Citations
2020
Year
closed
OA Status